ERBB2 and breast cancer: Despite the improvement in the clinical outcome of HER2+ BC patients, high heterogeneity characterizes the response to targeting agents [reviewed in (4, 99)] and patients can experience disease recurrence after curative intent and disease progression in the metastatic setting.